Latest news
Loading news…
LimmaTech Biologics is a biotech company that develops vaccines to prevent microbial infections and address antimicrobial resistance.
LimmaTech Biologics was acquired by Eli Lilly in 2026 for $780M.
Total Funding
Available in Pro Last Funding
Available in Pro Acquisitions
0
Investments
1
Monthly Visits
Available in Pro Contacts
4
Patents
10
3 trademarks
Company Details
Funding & Financials
Pro- Total funding
- Funding rounds
- Last funding
- Last funding type
- Last funding date
- Funding status
- Total equity funding
- Revenue range
Web Traffic
Pro- Monthly visits
- Global traffic rank
- 6-mo avg visits
- Visit duration (s)
- Pages / visit
- Bounce rate
- Rank change (mo)
Technology & IP
- Active technologies
- 5
- Patents granted
- 10
- Trademarks
- 3
- Top patent class
- Biochemistry; Beer; Spirits; Wine; Vinegar; Microbiology; Enzymology; Mutation Or Genetic Engineering
- IT spend
- $161K
Investor Activity
- Investments
- 1
- Portfolio orgs
- 1
Company Info
- Org types
- company, investor
- HQ
- Schlieren, Zurich, Switzerland
Signals & Scores
- Trend (7d)
- -1.1
- Trend (30d)
- -4.2
- Trend (90d)
- 7.9
Investments by LimmaTech Biologics
Loading columns…
0 of 0Show
Page 1 / 1
Key People at LimmaTech Biologics
CEO
CSO & Co-Founder
Co-Founder & CFO
4
professional contacts at LimmaTech Biologics
Contact execs at LimmaTech Biologics →Explore 200,000+ acquisitions — free
Filter the full database across sectors, companies, dates, and deal sizes. No signup, no paywall.
Recent News related to LimmaTech Biologics
Loading news…
FAQs about LimmaTech Biologics
People who checked this page also checked these
Browse the full Acquirezy directory.